QIAGENs innovative PrepAmp technology integrates sample preparation and detection in a single kit enabling throughput of more than 670 tests per PCR cycler in an eight-hour shiftCE-IVD marking for Europe and other countries worldwide EUA Emergency Use Application submission made in the U.S.Streamlined workflow cuts costs and plastic usage offering time to result of about two hoursQIAGEN announced the launch of the artus SARS-CoV-2 PrepAmp UM Kit which uses a liquid based sample preparation technology to simplify and increase COVID-19 testing throughput. The artus SARS-CoV-2 PrepAmp UM Kit has been CE-IVD registered for use in the European Union and other markets and an application for Emergency Use Authorization EUA has been submitted to the FDA allowing commercialization via notification in the US.QIAGENs innovative artus SARS-CoV-2 PrepAmp UM Kit integrates a liquid-based sample preparation that takes no more than two minutes with the provided real-time PCR assay. The kit uses common transport media like Universal Transport Media UTM as the starting material and provide all reagents required for sample to result on suspected SARS-CoV-2 patient samples.The streamlined workflow delivers results considerably faster than standard extraction-based Real-Time PCR processes and can support up to 672 samples per cycler in an eight-hour shift. Additionally due to the short workflow the quantity and volume of waste created is considerably lower.The artus SARS-CoV-2 PrepAmp UM Kit is based on the same technology that was launched in October 2020 as QIAprepamp for research applications. It has since proved its ability to detect the SARS-CoV-2 pathogen to be similar to regular PCR workflows.The launch of our artus SARS-CoV-2 PrepAmp test is an important step as it expands our portfolio of testing solutions for COVID-19 said Jean-Pascal Viola Senior Vice President Head of the Molecular Diagnostics Business Area and Corporate Business Development at QIAGEN. We continue to see the need for a large volume of PCR tests as COVID-19 cases continue around the world and our novel technology will enable clinical labs to drastically increase testing capacity with existing infrastructure. It is also an exciting and versatile technology with additional potential applications.QIAGEN has one of the most comprehensive SARS-CoV-2 research and testing portfolios. It includes sample preparation innovations like artus SARS-CoV-2 PrepAmp syndromic testing solution QIAstat-Dx high throughput PCR with its NeuMoDx devices QIAcuity digital PCR for wastewater testing applications QIAreach digital antibody and antigen tests and T-cell research solutions based on QIAGENs QuantiFERON IGRA technology. QIAGEN also has a range of products for NGS research into the SARS-CoV-2 virus and bioinformatic services and databases such as QDI QIAGEN Digital Insights.QIAGEN continues to add novel solutions to support laboratories combatting the pandemic and to provide experts with tools to learn more about the virus and drive forward research as well as providing solutions that will be relevant beyond the current pandemic.
🔍 Key Information
📄
Tender Reference No.
461797234
📅
Publication Date
21 Apr 2021
🌐
Sector
Healthcare Equipment and Services
📝
Notice Type
News
📍
Location
Germany
📁
Documents & Downloads
No documents found
🏷️ CPV
No CPV found
Need help with this bid?
Our bid experts can help you find, evaluate & win more tenders.